Rather than restating what mesenchymal stem cells are, we publish data other people do not have: what we charge and why, what our laboratory tests and discards, how we will report outcomes, and what international patients actually ask before they travel. Every report states its method, its limits and its update cycle.
Annual proprietary report
What regenerative medicine actually costs an international patient in Istanbul, itemised from the written quotes we issue, with the cost drivers and the items other clinics commonly leave out.
2026 (first edition) · Annual, next edition 2027
Annual proprietary report
The full release panel behind every cell and exosome product we administer: identity, viability, sterility, endotoxin, mycoplasma, traceability and the criteria that cause a batch to be discarded.
2026 edition · Annual, with interim updates when criteria change
Registry protocol and data dictionary
The protocol, definitions and reporting rules for our prospective outcomes registry — published before the data, so the method cannot be adjusted to flatter the result.
Protocol v1.0, first data cut scheduled 2027 · Annual data release after audit
Annual proprietary report
An annual read on who travels for regenerative medicine, what they ask before booking, and what actually decides their choice — with the survey instrument published alongside the findings.
2027 edition, methodology published 2026 · Annual
All reports are published under CC BY 4.0 with attribution. Corrections and data requests: contact the medical office.
Where this page sits in the wider picture.
